Altered thermal solubility measurement techniques are emerging as powerful tools to assess ligand binding, post-translational modification, protein-protein interactions, and many other cellular processes that affect protein state under various cellular conditions. Thermal solubility or stability pro...
Here, we proposed that the use of an HCP carrier proteome could enhance the acquisition of spectra from HCPs amidst a highly abundance therapeutic protein background to perform global HCP analysis. We provide proof of principle of this approach, which we term carrier proteome-HCP (CP-HCP) analysis, ...
We used TMT labelling to set up different experiment channels containing mixtures of the host cell carrier proteome (E coli) and mock biotherapeutic (BSA), to compare with interference detection channel to model and filter interference, a phenomenon where host cell proteins (HCPs) co-elute with high...
We added increasing amounts of E coli carrier proteome to BSA, our moch recombinant protein to model interference of high-background BSA peaks with smaller peaks of E coli HCPs, using MS2 and MS3 methods to show co-fragmentation and co-elution based on similar m/z ratio. We created an interference d...
Data from ProteomeXchange, PXD ID: PXD002093. File: m04675.mzml. Published as part of Mol Cell Proteomics. 2015 Jun 15 . From the Abstract: {{i}} Yeast (Saccharomyces cerevisiae) has served as a key model system in biology and as a benchmark for omics technology. Although near-complete proteomes of...
Data from ProteomeXchange, PXD ID: PXD001338. File: Hap2_fraction_5.mzml. Published as part of Mol Cell Proteomics. 2015 Jun 15 . From the Abstract: {{i}} Yeast (Saccharomyces cerevisiae) has served as a key model system in biology and as a benchmark for omics technology. Although near-complete pro...
We have created a CP-HCP method to characterise the carrier proteome of a host cell expression system producing recombinant protein biotherapeutic, which can be compared with the testing sample mixture containing trace amounts of host cell proteins against high-background recombinant protein and als...
Oncolytic viruses (OVs), known for their cancer-killing characteristics, overturn tumor-associated defects in antigen presentation through the MHC class I pathway and induce protective neo antitumor CD8 T cell responses. Nonetheless, whether OVs shape the tumor MHC-I ligandome remains unknown. Here,...
